Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- INmune Bio Inc. (NASDAQ:INMB) stock surged 50% as investors anticipate the upcoming release of top-line results from the company’s Phase 2 MINDFuL trial in early Alzheimer’s disease.
The clinical-stage inflammation and immunology company announced it will host a conference call on Monday, June 30 at 8:00 AM EDT to present the eagerly awaited data from its Alzheimer’s disease study.
The significant stock movement reflects heightened market interest in the trial outcomes, which could potentially impact the company’s development pipeline in neurodegenerative diseases. INmune Bio focuses on developing treatments that harness the patient’s innate immune system to fight diseases.
The MINDFuL trial represents an important milestone for INmune Bio as it evaluates the company’s approach to treating early Alzheimer’s disease, a condition affecting millions worldwide with limited effective treatment options currently available.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.